Brought to you by 
Cellectis, Pfizer to develop CART therapies for cancer
09 Nov 2021
Executive Summary
Pfizer Inc. and oncology firm Cellectis SA teamed up to develop chimeric antigen receptor T-cell (CART) cancer immunotherapies aimed at 15 targets selected by the Big Pharma and 12 targets chosen by Cellectis.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
- Immuno-Oncology
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cellectis, Pfizer to develop CART therapies for cancer
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice